Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter, Open-label, Phase II Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer

NCT04659382 is registered in ClinicalTrials.gov with Federation Francophone de Cancerologie Digestive as lead sponsor.

NCT NCT04659382
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04659382 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter, Open-label, Phase II Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer
Lead sponsor
Federation Francophone de Cancerologie Digestive
Phase
Phase 2
Overall status
Unknown status
Start date
October 7, 2020
Completion date
October 31, 2024
Enrollment
52 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

immune checkpoint inhibitor, internal radiotherapy, metastatic colorectal cancer, mss, pmmr